Navigation Links
Depomed Reports Second Quarter 2014 Financial Results
Date:8/6/2014

luted share
  • $223.7 million of cash and marketable securities and no debt outstanding as of June 30, 2014, an increase of $10.6 million for the quarter
  • Completed bench trial in ANDA litigation related to Gralise with a ruling expected in short order
  • Srinivas G. Rao, MD, PhD, joined Depomed in July as Chief Medical Officer and announced that R. Scott Shively will join the company as Chief Commercial Officer in September
  • "Gralise and our recent acquisitions, CAMBIA and Lazanda, led the way to a strong quarter, doubling our net product sales over the same period last year.  All four of our products showed prescription growth in Q2 compared to Q1 2014," said Jim Schoeneck, President and Chief Executive Officer of Depomed.  "We believe the growth of our product revenues in Q2 and the integration of new products into our commercial organization demonstrate our ability to build a growth-oriented specialty pharmaceutical company focused on pain and central nervous system disorders. We are also thrilled to add Srini and Scott to our leadership team, increasing our depth and expertise in the pain and CNS markets.  For the remainder of 2014, we are focused on growing product revenues, acquiring additional assets that will enhance our product portfolio and managing expenses to continue to operate at positive cash flow."

    Accounting Treatment for the Sale of Type 2 Diabetes Royalty and Milestone Interests to PDLIn October 2013, Depomed sold interests in future royalty and milestone payments in the Type 2 diabetes therapeutic area to PDL Biopharma, Inc. (PDL) for $240.5 million. As a result of ongoing supply order obligations with respect to the underlying royalties, Depomed is accounting for this transaction under the debt accounting method. Although the royalty and milestone payments were sold to PDL, debt accounting requires the Company to continue to recognize the underlying royalties and milestones as revenu
    '/>"/>

    SOURCE Depomed, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
    2. Depomed To Present At Jefferies 2012 Global Health Care Conference
    3. Depomed Announces Filing Of Shelf Registration To Replace Existing Shelf
    4. Depomed To Present At JMP Securities 7th Annual Healthcare Conference
    5. Depomed To Report Second Quarter Fiscal Year 2012 Financial Results On Thursday, August 2, 2012
    6. Depomed To Present At Stifel Nicolaus 2012 Healthcare Conference
    7. Depomed To Present At Morgan Stanley 2012 Healthcare Conference
    8. Depomed To Present At UBS Global Life Sciences Conference
    9. Depomed To Report Third Quarter Fiscal Year 2012 Financial Results On Monday, November 5, 2012
    10. Depomed Reports Third Quarter Financial Results
    11. Depomed To Present At Lazard 2012 Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/27/2015)... According to a new market research report ... Ablation Catheter (Cryoablation, RF, Microwave), Lab Devices (Mapping, Recording, ... Global Forecasts to 2019 ", published by MarketsandMarkets, the Electrophysiology ... by 2019 with a CAGR of around 10.3% during ... Browse   90   ma rket data T ...
    (Date:3/27/2015)... 2015   Hospira, Inc. (NYSE: ... the world,s leading provider of injectable drugs and ... evaluation of biosimilarity of its proposed biosimilar, Epoetin ... (FDA) conditionally approved name of RETACRIT™, compared to ... study data were presented at the National Kidney ...
    (Date:3/27/2015)... , March 27, 2015 ... 2015" therapeutic market research report of 52 pages ... online business intelligence library. The report ... on the therapeutic development for Visceral Pain, complete ... by drug target, mechanism of action (MoA), route ...
    Breaking Medicine Technology:Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4
    ... a world-leading developer and marketer of innovative medical technologies ... Ltd, a wholly-owned subsidiary of ConvaTec Holdings UK Ltd, ... a UK-based company that specialises in the discreet home ... As a well-respected company in the home ...
    ... President and CEO Randall Moreadith, MD, PhD, reported today that ... advance its lead oncology candidate SER-203 into a Phase I ... pleased to report to our existing and new shareholders the ... 2010. This is a very significant milestone for Serina Therapeutics, ...
    Cached Medicine Technology:ConvaTec Announces Acquisition of Trent Direct 2Serina Therapeutics, Inc. Closes $9.5 Million Financing Round 2
    (Date:3/28/2015)... 28, 2015 Designers and Professionals of ... entitled Scratches 5K from Pixel Film Studios. , “Scratches ... any media inside Final Cut Pro X” Said Christina ... time and is an effective tool for any FCPX ... Scratches 5K's intuitive grunge overlays. Simply drag title layers ...
    (Date:3/28/2015)... CA (PRWEB) March 28, 2015 ... specialists , this week released a report about the ... symptoms of asthma sufferers, and according to recent medical ... , According to the Environmental Protection Agency, people ... asthmatic reactions. Breathing in mold may trigger asthma attacks ...
    (Date:3/27/2015)... Island, NY (PRWEB) March 27, 2015 ... cancer-focused training and business criteria for the spa and ... services to clients who have experienced or are living ... the global Spafinder Wellness 365® Network, will be identified ... and recognized as a provider of safe, therapeutic services ...
    (Date:3/27/2015)... The federal court overseeing thousands of ... medication increases the risk that a patient will develop ... Dismiss four individual cases that had been filed in ... in the U.S. District Court, District of South Carolina, ... were warranted because the plaintiffs in those claims had ...
    (Date:3/27/2015)... March 27, 2015 Top medical tourism ... patients travel to the Dominican Republic to benefit from ... clinic is turning the medical tourism industry upside-down and ... — with trustworthy services becoming the central influence. ... plastic surgeon. Patients are not only attracted to low-cost ...
    Breaking Medicine News(10 mins):Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 4Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3Health News:Dominican Republic Plastic Surgery Provider Turning Medical Tourism Upside-Down 2Health News:Dominican Republic Plastic Surgery Provider Turning Medical Tourism Upside-Down 3
    ... many as 178 newborn babies died at a government-run ... Amar Agrawal told the state assembly Tuesday . ... about the lack of basic medical facilities at the ... reported 424 deaths of newly born babies in 2006 ...
    ... bird flu antibodies in migrant birds in five Siberian regions, ... ,"Out of over 4,000 samples taken in the ... to contain genetic material of the A-H5 virus and antibodies ... spokesman said the presence of antibodies meant that either the ...
    ... two studies indicate that elevated nonfasting triglyceride levels ... heart attack , with one study finding that ... this association. ,Triglyceride levels are usually ... certain types of lipoprotein particles (remnant lipoproteins), a ...
    ... patients a short course of corticosteroids after they have been ... of a relapse, a Cochrane Systematic Review has found. ... benefit lasts for about three weeks. ,This updated ... together involved 374 people. ,,Between 12% and 16% of ...
    ... is a more effective way of losing weight after pregnancy ... during pregnancy and many gradually lose it afterwards, but some ... retained body weight may be one factor that contributes to ... of returning to, and maintaining, pre-pregnant weights, and there is ...
    ... (saline) into your nose can help reduce the symptoms ... of the nasal passages. , ,Between 5% and ... passages (chronic rhinosinusitis). Many homoeopathic and yogic forms of ... symptoms, and it is now often recommended as part ...
    Cached Medicine News:Health News:High Nonfasting Triglyceride Levels Linked With Cardiovascular Risks 2
    1.0% Casein digest (NZ amine), 0.5% Sodium Chloride, 0.5% Yeast Extract, 1.0% bacto casamino acids, 0.2% Mag. Sulfate....
    0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride, 10mM Magnesium Chloride, 10mM Mag. Sulfate....
    Innovative hemi device combining anatomic design with the advanced material pyrocarbon....
    3.2% Tryptone, 2.0% Yeast Extract, 0.5% Sodium Chloride, pH 7.5....
    Medicine Products: